Dermatologic adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.
BRITISH JOURNAL OF DERMATOLOGY(2020)
摘要
Systemic inhibitors of mechanistic target of rapamycin (mTOR) have antiproliferative, antiangiogenic, and immunosuppressive properties. In dermatology, they are effective for managing certain vascular anomalies and genodermatoses, notably tuberous sclerosis complex (TSC). Compared to cancer patients or transplant recipients, TSC patients are prescribed mTOR inhibitors at lower doses and their treatment regimens are less likely to include other drugs that may induce similar side effects.
更多查看译文
关键词
Tuberous sclerosis complex,acne,adverse events,everolimus,mechanistic target of rapamycin inhibitors,oral mTOR inhibitors,oral ulcers,side effects,sirolimus,systemic mTOR inhibitors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要